Amarin investors know by now that the big news for the company will be whether its drug Vascepa gets new chemical entity, or NCE, status from the FDA, and so far, the wait has been long for an answer. In the meantime, the company is taking other measures to protect its drug from generic competition. Vascepa was just granted its ninth U.S. patent, and Amarin plans to apply for a 10th. In this video, Motley Fool analysts Max Macaluso and David Williamson discuss another factor that can give the company competitive leverage: increasing the number of suppliers it gets Vascepa's active ingredient from.